奈法红霉素用于社区获得性细菌性肺炎:针对人体临床开发项目的聚焦系统综述。
完整摘要 · 中文译文
背景:萘菲霉素是一种新型内酯酮内酯类抗菌药,正在开发用于社区获得性细菌性肺炎(CABP)的短程口服治疗。其临床开发计划包括在健康成人中开展的早期药代动力学研究以及在CABP患者中开展的后期疗效试验。本系统评价旨在综合现有关于其药理学、安全性和有效性的人体临床证据。 方法:本系统评价按照PRISMA 2020进行,并在PROSPERO注册(CRD420261367133)。检索了PubMed/MEDLINE、Embase、Scopus、CENTRAL、ClinicalTrials.gov和印度临床试验注册中心,检索时间自建库至2026年4月12日。评估萘菲霉素在人体中任何开发阶段的临床研究均符合纳入标准。研究筛选和数据提取由两名评价员独立完成。鉴于研究阶段、设计、人群和结局的异质性,研究结果采用叙述性综合。 结果:共纳入四项研究:两项在健康成人中开展的1期研究、一项2期随机对照研究以及一项在CABP成人中开展的3期随机非劣效性试验。早期研究提示萘菲霉素短期总体耐受性良好,其药代动力学特性支持每日一次给药,包括在上皮衬液和肺泡巨噬细胞中达到高肺暴露量。在2期研究中,萘菲霉素3天和5天方案的早期临床应答率均较高。在印度开展的3期试验中,3天口服萘菲霉素 该方案在第4天早期临床应答方面不劣于7天莫西沙星方案,两个治疗组均未报告重度治疗中出现的不良事件(TEAE)、严重TEAE或死亡。然而,证据基础在规模和地理多样性方面仍然有限,老年人、肾功能或肝功能损害患者以及微生物学确诊的大环内酯耐药肺炎球菌病患者的数据稀少。 结论:奈法红霉素是一种用于社区获得性细菌性肺炎(CABP)的短疗程口服候选药物,具有支持性的早期临床和药代动力学数据,但当前证据基础仍然有限。需要进一步证据以明确其普遍适用性、罕见或迟发性安全性特征,以及在微生物学确诊的大环内酯耐药肺炎球菌病中的有效性。
完整摘要 · 英文原文
BACKGROUND: Nafithromycin is a novel lactone ketolide being developed as a short-course oral treatment for community-acquired bacterial pneumonia (CABP). Its clinical development program includes early pharmacokinetic studies in healthy adults and later-phase efficacy trials in patients with CABP. This systematic review aimed to synthesize the available human clinical evidence on its pharmacology, safety, and efficacy. METHODS: This systematic review was conducted in accordance with PRISMA 2020 and registered in PROSPERO (CRD420261367133). PubMed/MEDLINE, Embase, Scopus, CENTRAL, ClinicalTrials.gov, and the Clinical Trials Registry - India were searched from inception to 12 April 2026. Clinical studies evaluating nafithromycin in humans at any stage of development were eligible. Study selection and data extraction were performed independently by two reviewers. Given heterogeneity in study phase, design, population, and outcomes, findings were synthesized narratively. RESULTS: Four studies were included: two Phase 1 studies in healthy adults, one Phase 2 randomized comparative study, and one Phase 3 randomized non-inferiority trial in adults with CABP. Early-phase studies suggested that nafithromycin was generally well tolerated in the short term and had pharmacokinetic properties supportive of once-daily dosing, including high pulmonary exposure in epithelial lining fluid and alveolar macrophages. In the Phase 2 study, early clinical response rates were high with both 3-day and 5-day nafithromycin regimens. In the Phase 3 trial conducted in India, a 3-day oral nafithromycin regimen was non-inferior to 7-day moxifloxacin for early clinical response at Day 4, with no severe TEAEs, serious TEAEs, or deaths reported in either treatment arm. However, the evidence base remains limited in size and geographic diversity, and data in older adults, patients with renal or hepatic impairment, and microbiologically confirmed macrolide-resistant pneumococcal disease were sparse. CONCLUSIONS: Nafithromycin is a short-course oral candidate for CABP with supportive early clinical and pharmacokinetic data, but the current evidence base remains limited. Further evidence is needed to clarify its generalisability, rare or delayed safety profile, and effectiveness in microbiologically confirmed macrolide-resistant pneumococcal disease.